Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.

Completed

Conditions studied: HIV Infections

In brief

The goal of this demonstration project or observational study is to evaluate the feasibility and acceptability of a pharmacist-managed cabotegravir long acting injectable for PrEP program in a community pharmacy setting. The main question it aims to answer are: * Is the program feasible and acceptable at the end of 1 year of operations? * What are the facilitators and barriers of the program? Participants who want to start the FDA approved cabotegravir long acting injectable medication for PrEP will have the option participating in surveys and a review of their electronic health records. Medication will be administered based on FDA approved labeling guidelines and their PrEP care will be part of standard of care per CDC. Pharmacists who want to provide the service to their patients will have the option of participating in surveys pre and post implementation.

Key facts

Study ID

NCT05867212

Run by

Kelley-Ross & Associates, Inc.

People needed

50

Starts

2023-05-13

Expected to finish

2025-04-30

Last updated by the study team

2025-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18 years of age or older at the time of screening
• Weight ≥ 35 kg
• HIV-negative status
• Willing to provide informed consent and undergo all required study procedures.

You may not qualify if…

• Unknown or positive HIV status
• Coadministration of drugs that significantly decrease cabotegravir concentrations according to the FDA package insert.
• Any participants that do not meet criteria for management under CDTA

Where it is running

• Kelley-Ross Pharmacy at the Polyclinic — Seattle, Washington, United States
• Kelley-Ross Capitol Hill Pharmacy — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.